N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

March 31, 2014

Study Completion Date

May 31, 2015

Conditions
Neuroblastoma
Interventions
DRUG

fenretinide lipid matrix

DRUG

ketoconazole

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (11)

30342

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta

60637

University of Chicago Comer Children's Hospital, Chicago

76104

Cook Children's Medical Center - Fort Worth, Fort Worth

94143

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

94304

Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

90027-0700

Childrens Hospital Los Angeles, Los Angeles

02115

Children's Hospital Boston, Boston

48109-0286

C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

19104-4318

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Hospital Los Angeles

OTHER

NCT00295919 - N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma | Biotech Hunter | Biotech Hunter